Distribuzione geografica
Continente #
NA - Nord America 5944
EU - Europa 1085
AS - Asia 368
Continente sconosciuto - Info sul continente non disponibili 7
SA - Sud America 3
OC - Oceania 1
Totale 7408
Nazione #
US - Stati Uniti d'America 5938
SE - Svezia 423
CN - Cina 324
FR - Francia 218
IT - Italia 204
DE - Germania 62
FI - Finlandia 56
GB - Regno Unito 45
BE - Belgio 32
VN - Vietnam 21
IE - Irlanda 17
UA - Ucraina 12
IR - Iran 9
EU - Europa 7
CA - Canada 5
IN - India 5
AT - Austria 3
ID - Indonesia 3
TR - Turchia 3
BR - Brasile 2
CZ - Repubblica Ceca 2
HR - Croazia 2
PT - Portogallo 2
RO - Romania 2
AR - Argentina 1
AU - Australia 1
BG - Bulgaria 1
DO - Repubblica Dominicana 1
ES - Italia 1
HK - Hong Kong 1
JP - Giappone 1
LV - Lettonia 1
MN - Mongolia 1
NO - Norvegia 1
SI - Slovenia 1
Totale 7408
Città #
Fairfield 1062
Woodbridge 688
Houston 635
Chandler 553
Ashburn 446
Seattle 430
Ann Arbor 382
Cambridge 374
Nyköping 360
Wilmington 319
Lawrence 122
Roxbury 116
Beijing 101
Jacksonville 85
Bari 80
Nanjing 78
Des Moines 76
Inglewood 65
Princeton 57
San Diego 44
Brussels 32
Shenyang 31
Dearborn 28
Paris 27
Dong Ket 21
Nanchang 20
Dublin 17
Brooklyn 16
Jiaxing 15
London 15
Redwood City 14
Hebei 13
Tianjin 12
Boardman 11
Changsha 11
San Mateo 11
Guangzhou 8
Ardabil 7
San Francisco 7
Giovinazzo 6
Hefei 6
Milan 6
Augusta 5
Indiana 5
Jinan 5
Falls Church 4
Leawood 4
Toronto 4
Cerignola 3
Detroit 3
Hangzhou 3
Helsinki 3
Norwalk 3
Simi Valley 3
Taizhou 3
Taranto 3
Vienna 3
Wiesbaden 3
Avegno 2
Bitonto 2
Castellamonte 2
Massa 2
Monmouth Junction 2
Nagold 2
Ningbo 2
Nürnberg 2
Shanghai 2
Terlizzi 2
Zhengzhou 2
Zogno 2
Buffalo 1
Chapel Hill 1
Chicago 1
Chongqing 1
Dallas 1
Florence 1
Gallarate 1
Harbin 1
Jakarta 1
Johanneshov 1
Kunming 1
Lanzhou 1
Ljubljana 1
Manduria 1
Markham 1
Marseille 1
Melbourne 1
Monopoli 1
New York 1
Oklahoma City 1
Oslo 1
Prague 1
Riga 1
Sabz 1
Saint Louis 1
Santo Domingo 1
Shaoxing 1
Stockport 1
Targoviste 1
Tokyo 1
Totale 6518
Nome #
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection 132
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study 126
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors 119
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study 117
Basic characteristics of adults with periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome in comparison with the typical pediatric expression of disease 111
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 108
Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis 107
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis 103
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 103
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study 102
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 102
Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases 100
Management of Small Vessel Vasculitides 100
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives 100
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 99
Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life 98
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 97
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis 97
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease 96
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome 95
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate 94
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 94
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. 93
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases 93
Serum amyloid-A in Behçet's disease 91
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa 91
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab 91
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy 89
Untangling the web of systemic autoinflammatory diseases 89
Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study 88
Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives 87
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 87
null 86
A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome 83
Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art 83
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema 83
null 82
null 81
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 81
null 80
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 79
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 76
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 76
Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials 75
Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis 74
null 74
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings 74
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 73
null 72
null 72
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 72
The protean ocular involvement in monogenic autoinflammatory diseases: state of the art 72
null 71
null 70
IL-6 blockade in the management of non-infectious uveitis 69
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 69
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 68
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 67
AB0369 Adult-onset still’s disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience 66
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 66
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 65
Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review 64
Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease 63
null 63
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 63
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 63
Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics 63
null 62
null 62
Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study 62
Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study 59
null 59
Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for behcet's disease 57
The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors 56
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 54
Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy 52
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 52
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings 52
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 52
improvement of refractory dysphagia in patients with idiopathic inflammatory myopathies receveing immunoglubulin intravenous therapy 48
null 43
Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients 43
null 41
null 41
Improvement of Refractory Dysphagia in Patients with Idiopathic Inflammatory Myopathies Receveing Immunoglobulin Intravenous Therapy 40
Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey 40
Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis 39
The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment 39
Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series 37
null 36
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers 35
null 35
Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy 35
null 34
Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease 33
Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease 32
null 30
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis 30
Totale 7237
Categoria #
all - tutte 17795
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17795

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201813 0000 00 00 0841
2018/2019696 231101 319 819 16119239238
2019/20202449 3156849173 268234 257311 34515718488
2020/20211482 8514011159 251139 130127 1181399687
2021/2022959 73402038 3981 6352 7079119285
2022/20231448 213194123116 116238 42199 207000
Totale 7979